GSK To Co-Promote Advair With Mitsubishi Tanabe Pharma In Japan
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline and Mitsubishi Tanabe Pharma will be co-promoting chronic obstructive pulmonary disease treating Advair Diskus (fluticasone propionate plus salmeterol) staring April. Through the collaboration, GSK aims to increase awareness and provide Japanese patients information on the drug as a treatment option. In Japan, there are 4.5 million COPD patients and 2,500 people die of the disease annually. (Click here for more - Japanese language)
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.